Logo

BHST

BioHarvest Sciences Inc. Common Stock

BHST

BioHarvest Sciences Inc. Common Stock • NASDAQ
$6.73 ▼ -0.30% (-0.02)
Market Cap $117.13 M
52w High $12.80
52w Low $4.72
Dividend Yield 0%
P/E -9.9
Volume 16.14K
Outstanding Shares 17.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $9.067M ▲ $6.49M ▼ $-2.513M ▲ -27.716% ▲ $-0.14 ▲ $-535K ▲
Q2-2025 $8.515M ▲ $6.901M ▲ $-4.08M ▼ -47.915% ▼ $-0.24 ▼ $-1.408M ▼
Q1-2025 $7.86M ▲ $6.314M ▲ $-2.338M ▲ -29.746% ▲ $-0.13 ▲ $-1.32M ▲
Q4-2024 $7.278M ▲ $5.81M ▼ $-2.956M ▼ -40.616% ▲ $-0.17 ▼ $-1.346M ▲
Q3-2024 $6.539M $5.816M $-2.689M -41.122% $-0.16 $-1.751M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.966M ▲ $35.188M ▲ $27.453M ▼ $7.735M ▲
Q2-2025 $3.727M ▲ $27.798M ▲ $32.021M ▲ $-4.223M ▼
Q1-2025 $3.401M ▲ $26.591M ▲ $27.467M ▲ $-876K ▼
Q4-2024 $2.39M ▼ $25.001M ▼ $23.671M ▲ $1.33M ▼
Q3-2024 $2.768M $25.823M $21.684M $4.139M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.513M ▲ $-2.114M ▼ $-427.602K ▲ $9.867M ▲ $7.239M ▲ $-2.542M ▼
Q2-2025 $-4.08M ▼ $-1.509M ▼ $-615.22K ▲ $2.487M ▼ $326K ▼ $-2.124M ▼
Q1-2025 $-2.338M ▲ $-1.427M ▲ $-680K ▼ $3.122M ▲ $1.011M ▲ $-2.111M ▲
Q4-2024 $-2.956M ▼ $-2.948M ▼ $-348.582K ▲ $3.012M ▲ $-378K ▲ $-3.293M ▼
Q3-2024 $-2.689M $-1.759M $-472K $-164K $-2.4M $-2.271M

Five-Year Company Overview

Income Statement

Income Statement The company is still in an early commercial stage. Sales exist but are very small and not yet sufficient to cover operating costs. Losses have been steady for several years, which is typical for a young biotech platform business that is investing heavily in growth and commercialization. Profitability is not yet in sight based on the recent trend, so the story is still mainly about future potential rather than current earnings strength.

Balance Sheet

Balance Sheet The balance sheet is thin and shows signs of strain. Assets are modest, cash on hand has been limited, and debt has crept up. Shareholder equity hovers around breakeven and has recently been slightly negative, a sign that past losses have accumulated faster than capital has come in. This leaves the company dependent on continued access to outside funding and careful management of its obligations.

Cash Flow

Cash Flow Operating cash flow has been consistently negative, reflecting ongoing spending on R&D, commercialization, and overhead without matching cash inflows from sales. Free cash flow is also negative, meaning the business currently consumes cash rather than generates it. Capital spending appears light, so most outflows are likely tied to people, infrastructure, and marketing rather than large physical assets. The company will likely need recurring capital infusions unless it can scale revenues meaningfully.

Competitive Edge

Competitive Edge BioHarvest appears to have a distinctive position built on a proprietary plant-cell cultivation platform rather than traditional farming. Its technology aims to deliver more consistent, cleaner, and potentially cheaper active ingredients than conventional agricultural sources. Patent protection, long technical know‑how, and being an early mover in commercializing these nutraceutical products provide some barriers to entry. However, the firm is still small, surrounded by many larger and better-funded competitors in supplements, cannabis, and ingredients, so converting this technical edge into durable market share is still an open question.

Innovation and R&D

Innovation and R&D Innovation is the core of the company’s story. Its Bio‑Plant CELLicitation platform, VINIA flagship product, cannabis and hemp applications, and emerging CDMO services all point to a versatile technology base. The company is pushing into new areas such as plant-based exosomes for skincare, additional botanicals (like saffron, olives, and pomegranates), and pharmaceutical collaborations. This broad pipeline offers multiple shots on goal, but it also raises execution risk, as management must prioritize and successfully commercialize several complex projects at once.

Summary

BHST is a high-innovation, early-stage biotech platform business trying to redefine how plant-based ingredients are produced. The financials show a company still firmly in build-out mode: small but growing revenues, persistent losses, negative cash flow, and a stretched balance sheet. On the strategic side, the technology platform, patent base, and first-mover status in certain niches create a potentially attractive moat, with opportunities across nutraceuticals, cannabis, cosmetics, and pharma services. The key uncertainties are execution, timing to scale, and ongoing access to capital while the company works to turn promising science into a sustainable, self-funding business.

NEWS

November 13, 2025 · 4:05 PM UTC

BioHarvest Sciences Reports Third Quarter 2025 Financial Results

Read more

November 12, 2025 · 8:42 AM UTC

BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025

Read more

November 10, 2025 · 4:18 PM UTC

BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares

Read more

November 7, 2025 · 7:30 AM UTC

BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock

Read more

November 6, 2025 · 4:37 PM UTC

BioHarvest Announces Proposed Public Offering of Common Stock

Read more